Kiniksa Pharmaceuticals International

KPL-387 is a small-molecule therapeutic candidate developed by Kiniksa Pharmaceuticals International, plc for the treatment of pericarditis, an inflammatory condition of the heart's outer membrane. The program is currently in Phase 3 clinical development. As of May 2026, the program remains active with the most recent milestone dated 19 May 2026, though specific details of that milestone have not been disclosed. KPL-387 represents part of Kiniksa's broader pericarditis portfolio, which includes the approved therapy Rilonacept and the earlier-stage candidate KPL-914. The company's strategy appears focused on addressing recurrent and acute pericarditis through multiple mechanistic approaches. Regulatory approval status and specific mechanism of action for KPL-387 have not yet been disclosed. The program is supported by clinical trial NCT07010159, which is actively enrolling or ongoing.

Kiniksa's development of KPL-387 occurs within a competitive landscape that includes other small-molecule candidates such as Cardiol Therapeutics' 100-006 and CardiolRx, both also in Phase 3 development for pericarditis indications. The Phase 3 status of KPL-387 indicates the program has progressed through earlier-stage development and is now evaluating efficacy and safety in larger patient populations. Peak sales projections, consensus positioning, and detailed clinical endpoints remain proprietary or not yet disclosed. The next anticipated milestone and timeline for regulatory submission or approval have not been publicly communicated.

Pericarditis, particularly recurrent forms, represents a significant unmet medical need characterized by inflammation of the pericardium that can lead to complications including constrictive pericarditis and tamponade. Current treatment options are limited, and many patients experience recurrent episodes despite conventional anti-inflammatory therapy. The market for pericarditis therapeutics has expanded following regulatory approvals of colchicine and IL-1 inhibitors, establishing proof-of-concept for targeted anti-inflammatory approaches in this indication.

KPL-387's Phase 3 status positions it as a potential near-term entrant to this emerging market. The competitive presence of multiple Phase 3 candidates from different sponsors suggests growing recognition of pericarditis as a commercially viable indication. Kiniksa's dual approach—combining the approved Rilonacept with investigational candidates KPL-387 and KPL-914—indicates strategic depth in addressing different patient populations or disease subtypes within pericarditis.

The patient population for pericarditis includes both acute and recurrent presentations, with recurrent pericarditis affecting approximately 5-30% of initial pericarditis cases. Commercial significance is supported by the chronic, relapsing nature of the condition and the potential for long-term treatment. KPL-387's small-molecule modality may offer advantages in oral bioavailability, patient convenience, and manufacturing scalability compared to biologic alternatives, potentially influencing competitive positioning and market penetration.

Drug Class: Small-molecule anti-inflammatory candidate

Modality: Small molecule

Indication: Pericarditis

Mechanism of Action: Not yet disclosed

Molecular Target: Not yet disclosed

Route of Administration: Not yet disclosed

Related Therapies from Sponsor: Rilonacept (approved IL-1β inhibitor for pericarditis), KPL-914 (Phase 2 small-molecule candidate for pericarditis)

First Approval Status: Not approved; currently in Phase 3 development

Patent Status: Not yet disclosed

• KPL-387 is a small-molecule therapeutic distinct from Kiniksa's biologic Rilonacept, suggesting a complementary mechanistic or formulation strategy
• The Phase 3 designation indicates completion of Phase 2 efficacy and safety assessments with progression to larger confirmatory trials
• Specific pharmacokinetic properties, dosing regimen, and administration route remain proprietary information

FDA Status: Not yet disclosed. KPL-387 is in Phase 3 development; regulatory pathway and breakthrough designation status (if any) have not been publicly communicated.

EMA Status: Not yet disclosed.

PMDA (Japan) Status: Not yet disclosed.

NMPA (China) Status: Not yet disclosed.

• No approval date, conditional approval, or accelerated review designation has been announced for KPL-387
• Regulatory submission timeline and expected approval date are not yet disclosed
• Breakthrough Therapy Designation, Fast Track status, or other expedited pathways (if granted) have not been communicated
• Kiniksa's approved Rilonacept provides precedent for pericarditis indication approvals by the FDA, but KPL-387's specific regulatory strategy remains undisclosed

Strategic Implications: Kiniksa's pursuit of KPL-387 alongside the approved Rilonacept and Phase 2 KPL-914 suggests a multi-pronged strategy to capture different segments of the pericarditis market. The small-molecule approach of KPL-387 may target patients who prefer or require oral administration, complementing the biologic profile of Rilonacept. This portfolio diversification reduces dependence on a single mechanism and hedges against competitive or regulatory setbacks.

Competitive Implications: The Phase 3 status of competing programs from Cardiol Therapeutics (100-006 and CardiolRx) indicates a race to market. KPL-387's timeline to approval will be critical; delays could allow competitors to establish market position first. Conversely, if KPL-387 demonstrates superior efficacy, safety, or convenience, it could capture significant market share despite later entry.

Future Catalysts: Key milestones include Phase 3 trial readouts (expected timing not disclosed), regulatory submissions, and potential FDA approvals. Publication of Phase 3 efficacy and safety data in peer-reviewed journals would provide independent validation. Regulatory decisions from the FDA and EMA will determine market access and reimbursement prospects. Competitive approvals from Cardiol Therapeutics would establish pricing benchmarks and market demand.

Expected Milestones: Phase 3 trial completion and top-line data readout represent the nearest anticipated catalyst. Regulatory submission is likely to follow positive Phase 3 results. Approval timelines will depend on regulatory agency review timelines and any requests for additional data. Commercial launch would follow regulatory approval, contingent on reimbursement negotiations and market access agreements.